We develop and analyse a mathematical model of tumour-immune interaction that explicitly incorporates heterogeneity in tumour cell cycle duration by using a distributed delay dierential equation. Our necessary and sucient conditions for local stability of the cancer free equilibrium completely characterise the importance of tumour-immune interaction in disease progression. Consistent with the immunoediting hypothesis, we show that decreasing tumour-immune interaction leads to tumour expansion. Finally, we show that immune involvement is crucial in determining the long-term response to viral therapy.
Introduction
Malignant tumours contain a highly heterogeneous population of cells that have distinct genotypes and reproductive abilities [Bell and McFadden, 2014; Lichty et al., 2014] . The heterogeneous nature of tumours is mirrored in the reproduction speed of malignant cells. Most existing mathematical models greatly simplify the impact of heterogeneity in cell cycle times by either neglecting the cell cycle or assuming that all tumour cells have identical cell cycle durations. We will account for the range of cell cycle durations by deriving a mathematical model of tumour growth using a delay dierential equation (DDE) with a distribution of delays. This is, to our knowledge, a novel method of considering the heterogeneity present in malignant tumours and presents a physiologically realistic model of tumour expansion. Distributed DDEs model a continuum of cell cycle durations that belong to an interval of physiologically realistic values, with durations distributed according to a probability density function (PDF). Representing the time length of the cell cycle by a distributed DDE explicitly allows for variability in cell cycle duration. This contrasts with discrete DDEs, where the discrete delay represents the cell cycle duration which is taken to be the same for all tumour cells. Thus discrete delays implicitly assume homogeneity of the tumour cell cycle duration which limits the physiological relevance of such models. The human immune system attempts to eradicate malignant cells and inhibit tumour establishment [Hallam et al., 2009; Hoos et al., 2011] . We study this phenomenon by explicitly including tumour-immune interaction in our mathematical model. Analysis of this model shows that there is a threshold tumour size below which the immune system successfully prevents tumour establishment and quanties the role of immune surveillance in tumour establishment and growth.
Therapeutic strategies under development attempt to exploit the immune system to eradicate malignant tumours via immuno-oncology and genetically engineered oncolytic viruses [Cassady et al., 2016; Chiocca and Rabkin, 2015; Hoos et al., 2011; Lawler and Chiocca, 2015] . Oncolytic viruses are designed to exploit the high reproductive rate characteristic of malignant tumours and preferentially infect cancerous cells. Immune regulated death of infected tumour cells releases tumour specic antigens that signal the immune system [Breitbach et al., 2016] . We incorporate oncolytic viral therapy into our mathematical model to study how these viruses can prime the immune system to eliminate tumours. The release of tumour specic antigens induces a long-lasting immune response that causes tumour regression which persists after resolution of the infection [Bourgeois-Daigneault et al., 2016] . Consequently, oncolytic viruses have recently been recast as instigators of immuno-oncology and are being engineered to induce immune recruitment. For example, in 2015, the United States Food and Drug Administration approved a modied herpes virus that promotes granulocyte-macrophage colony-stimulating factor production and resulting anti-tumour immunity for treatment of melanoma [Bommareddy et al., 2017] . Mathematical models have been used extensively to understand and predict tumour growth and tumourimmune interactions (see Santiago et al. [2017] ; Walker and Enderling [2016] ; Wodarz [2016] for reviews). Existing models range from formulations as ordinary dierential equations (ODEs) [Idema et al., 2010; Kim et al., 2015; Kirschner and Panetta, 1998; MacNamara and Eftimie, 2015] , to partial dierential equations [Hillen et al., 2013; Malinzi et al., 2017] and discrete DDEs [Liu et al., 2007; Mahasa et al., 2017; Villasana and Radunskaya, 2003] . Crivelli et al. [2012] developed and analysed a discrete DDE model of tumour growth and viral oncology. The Crivelli model is simple enough to be analytically tractable while retaining important physiological aspects of tumour growth and oncolytic viral therapy, but neglects the role of the immune system in tumour eradication. Crivelli et al. [2012] model the interaction of virions and tumour cells by using a non-dierentiable function which signicantly complicates the analysis of the model. This contact function allows for viral therapy alone to drive tumour remission in their model, without interaction with the immune system. We develop a tumour growth and viral oncology model which incorporates immune recruitment to drive tumour clearance. Our model is partly based on the Crivelli model but augments and generalises it in very signicant ways. We explicitly model phagocytosis of the tumour cells, and cytokine driven phagocyte recruitment. As mentioned, we also include a distribution of cell cycles times for the tumour cells which results in a DDE with distributed delays. The inclusion of a heterogeneous cell cycle duration is more realistic than models with a discrete delay, because a discrete delay is equivalent to assuming that that every cell in the tumour has a constant and identical cell cycle duration. We show the explicit link between our work and Crivelli et al. [2012] in Appendix A. The distributed DDE tumour-immune model is developed in full generality in Section 2. In Section 3, we prove that solutions of the initial value problem evolving from non-negative initial data remain nonnegative. Next, in Theorem 3.3, we determine a condition for treatment free extinction of the tumour that quanties the link between immune involvement and disease progression. Our results show that immune involvement is crucial in controlling tumour growth. As a direct consequence, we show in Corollary 3.4 that homogeneous tumours are less robust than tumours with heterogeneous cell cycle durations. Finally, by showing the existence of a cancer-immune co-existence equilibrium in Theorem 3.5, we establish a direct link between the minimal viable tumour size and the immune killing capacity that is consistent with the immunoediting hypothesis of tumour progression [Mittal et al., 2014] . In Section 4, by deriving a variant of the linear chain technique, we prove that the distributed DDE is equivalent to a nite dimensional ODE. We end Section 4 by simulating viral oncology treatment and illustrating the previously derived stability results. Our simulations show the existence of a transcritical bifurcation where the unstable nonzero equilibrium acts as a separatrix between tumour extinction and growth. Biologically, this result implies that treatment strategies that force the malignant tumour across the separatrix will eradicate the tumour. Moreover, we show that suciently strong immune involvement can counteract aggressive tumour growth and lead to tumour extinction without treatment. Finally, we discuss our results in Section 5.
Model Development
Our model of tumour-immune interaction is given by the system of dierential equations
In equation (1), Q(t) and G 1 (t) denote the quiescent and proliferative phase tumour cells. The cytokine concentration is denoted by C(t), and the phagocyte concentration in the tumour microenvironment by P (t). Finally, V (t) is the concentration of oncolytic virions and I(t) is the number of infected tumour cells. In the Burns and Tannock [1970] model of the cell cycle, Q(t) corresponds to cells in the G 0 phase while G 1 (t) corresponds to the G 1 phase. We consider the S, G 2 and M phases to be the active phases of the cell cycle, which we model as a process rather than as populations. In a similar manner to Crivelli et al. [2012] ; Dawson and Hillen [2006] and Liu et al. [2007] , we use a constant transition rate from G 0 to G 1 . The G 1 -S and the G 2 -M checkpoints have been explored as targets of emerging cancer treatment [Dominguez-Brauer et al., 2015; Matheson et al., 2016; Visconti et al., 2016] . By separating the G 1 phase from the S, G 2 and M phases, our model could be easily adapted to include the precise eects of interventions that arrest the cell cycle at the G 1 -S checkpoint, such as cyclin dependent kinase inhibitors [Dominguez-Brauer et al., 2015] . It would also be possible to incorporate drug induced cell cycle arrest at the G 2 -M checkpoint by decreasing mitotic output (without eecting transition across the G 1 -S checkpoint), similar to emerging treatments discussed by Dominguez-Brauer et al. [2015] ; Visconti et al. [2016] . We denote by N (t) the total number of cells in the active portion (the S, G 2 and M phases) of the cell cycle, given by
as derived in Appendix B. In equations (1) and (2) the distribution of the duration of the active phase of the cell cycle is described by the PDF K(t). We do not choose a specic distribution in our model; see Section 2.1 for a discussion of the properties of K(t). The functions η(U (t)), ψ Q (U (t)), ψ G (U (t)), ϕ(C(t)), and C prod (U (t)) in equation (1) are dened in equations (8), (10), (11) and (13). To simplify notation, we denote the vector
The distributed DDE is given initial data Q(t 0 ), s) to create an initial value problem. For simplicity, we take t 0 = 0. Figure 1 : Pictorial representation of the tumour growth model. Populations are denoted by circles, processes by squares and rates by arrows. Quiescent cells enter G 1 (t) at rate a 1 and undergo apoptosis at rate d 1 . Cells leave G 1 (t) and enter the active phase of the cell cycle at rate a 2 while undergoing apoptosis at a rate d 2 . The active phase death rate isd k and cells re-enter quiescence after mitosis. Phagocytes interact with quiescent and G 1 phase cells at respective rates ψ Q and ψ G . Tumour-immune interaction drives cytokine production through the function C prod .
We derive equation (1) in three steps. First, we consider tumour growth in the absence of immune interaction and viral therapy in Section 2.1. Tumour heterogeneity is explicitly accounted for by using a distributed cell cycle time length. The tumour growth equations are derived keeping in mind the eventual use of the model to describe the impact of an RNA oncolytic virus on tumour growth. Next, in Section 2.2, we derive the tumour-immune interaction and incorporate immunosurveillance into the tumour growth model. The graphical representation of the tumour-immune growth model is given in Figure 1 . Finally, by including viral therapy and immune recruitment in Section 2.3, we arrive at equation (1).
Tumour Growth Model Development
RNA viruses replicate in infected cells during stages G 1 through M of the Burns and Tannock [1970] model of the cell cycle. As previously noted, we separately model the quiescent (Q(t)) and G 1 phase (G 1 (t)) tumour cell populations. Quiescent tumour cells undergo apoptosis at a rate d 1 . We denote the transit rate between the quiescent and G 1 population as a 1 . Cells in G 1 undergo apoptosis at a rate d 2 , and enter into the active phase of the cell cycle at a rate a 2 . We dene the cell cycle duration as the time length of the active portion of the cell cycle, calculated as the time a cell takes between exiting G 1 and re-entering Q.
We assume that the cell cycle time of tumour cells is a positive random variable with PDF K(t) satisfying
We assume that cells have an expected mean cell cycle duration of τ , so the expected value of K(t) satises
We will also use that
where in particular we note that the Laplace transform L[K](λ) of the PDF K(t) is equivalent to E K (e −λt ) since
Let A R (t) denote the rate that successfully dividing cells re-enter quiescence at time t. Such cells began the active portion of the cell cycle some time σ in the past at rate a 2 G 1 (σ). The likelihood that these cells complete the cell cycle at time t is given by K(t − σ). Disregarding immune interaction for now, cells in the active portion of the cell cycle undergo apoptosis at a constant, distribution specic, rated K . Consequently, cells that spend more time in the active phase of the cell cycle are more likely to undergo apoptosis instead of completing the cell cycle and returning to quiescence. Thus
Later, we will update A R (t) to include tumour-immune interaction and viral therapy. The distributed delay expression A R (t) is a novel model of tumour cell reproduction which is more physiologically appropriate than a discrete delay. The discrete delay model considered by Crivelli et al. [2012] corresponds to K(t) = δ(t − τ ) and d δ = d 3 . The explicit link between equation (1) and the Crivelli model is shown in Appendix A. The expected cellular output of the cell cycle with a discrete and xed duration is
To ensure a consistent cellular output from the cell cycle for dierent distributions K(t), we dened K > 0 as the distribution dependent unique positive value that solves
The parameterd K must exist for a given distribution K as the function
is continuous and satises
The intermediate value theorem along with the fact that f (ζ) is strictly decreasing for ζ > 0 guarantees the existence and uniqueness ofd K .
The resulting model of tumour growth without immunosurveillance is then d dt
where A R (t) is given by (6).
Immune Model Development
The tumour microenvironment is complex and contains a multitude of cytokines and cell types [Bartlett et al., 2013; Cassady et al., 2016; Grivennikov and Karin, 2011; Hallam et al., 2009] . To avoid overcomplicating the model by adding variables and creating equations corresponding to each cytokine and signalling pathway, we instead model a general local proinammatory cytokine compartment C(t). We assume the cytokine is produced at a variable rate C prod (U (t)) with the homeostatic production rate C * prod . The viral and immune mediated destruction of tumour cells results in increased cytokine production by releasing tumour specic antigens [Bartlett et al., 2013; Bell and McFadden, 2014] . Conversely, we do not consider apoptosis of tumour cells to be immunogenic [Bartlett et al., 2013] . Therefore, C prod (U (t)) is an increasing function of viral and immune destruction of tumour cells. The resulting positive feedback loop is consistent with self activation of immune cells observed experimentally [Mosser, 2003] . Finally, we assume that the cytokine is cleared linearly at rate k elim , mimicking the dynamics of many endogeneous cytokines [Craig et al., 2016; Krzyzanski et al., 2010; Piscitelli et al., 1997] . The simplied cytokine dynamics are thus given by d dt
We assume that phagocytes can undergo phagocytosis multiple times, so phagocyte clearance is linear, and we do not include a phagocytosis related death term. Inammatory cytokines drive phagocyte recruitment and activation [Bartlett et al., 2013; Cassady et al., 2016; Hallam et al., 2009] . Consequently, we model the local phagocyte population in a similar cytokine driven manner to Schirm et al. [2016] by using a Michaelis-Menten growth function ϕ(C(t)) with maximal production rate k cp and half eect concentration of cytokine C 1/2 . The phagocyte dynamics are therefore given by
The disease free equilibrium concentrations of (C(t), P (t)) represent the tumour-free tissue concentrations of cytokine and phagocytes and are given by
We describe phagocyte-tumour cell interaction by
For small tumour cell populations, the tumour-immune interaction follows mass-action kinetics, while for large tumour cell populations, the phagocytosis rate is limited by the phagocyte concentration as would be expected. We assume that cells in the active portion of the cell cycle interact with the immune system in the same way as cells in the G 1 phase. The total immune mediated death is then
Contact rates similar to equation (10) were derived by Imran and Smith [2007] using a handling time argument.
2.3 Viral Therapy Model Development Viral infections are caused by virus specic particles, called virions, that infect and replicate in host cells. Infected host cells die after undergoing lysis and releasing virions into the surrounding tissue. To model the eect of oncolytic virus treatment, we consider the virion population, V (t), and the number of infected malignant cells, I(t). Infection occurs following contact of a virion and a susceptible cell. Susceptible cells are cells in the G 1 , S, G 2 and M phases of the cell cycle. We model the infection rate between virions and susceptible cells by η(U (t)). Infection due to virion and susceptible cell contact occurs in a similar manner to tumour-immune interactions. Consequently, η(U (t)) is structured similarly to equation (10), with half eect concentration η 1/2 and maximal infectious rate κ, so
As previously noted, disease remission following viral therapy is thought to result from activation of the immune system against the tumour and increased antitumour immunity [Bartlett et al., 2013; Bell and McFadden, 2014; Cassady et al., 2016; Fukuhara et al., 2016; Rehman et al., 2016] . Therefore, introduction of viral therapy alone should not impact the stability of the disease free equilibrium but rather immune response to viral therapy may change the quantitative behaviour of solutions. This is in contrast to Crivelli et al. [2012] , who modelled contact between virions and susceptible cells using a non-dierentiable contact function. Their choice of contact function was motivated by noting that viral therapy has driven cancer into remission, which implicitly assumed that the virus alone drives disease remission. Infected tumour cells are produced following infection and undergo lysis at a rate δ. Lysis of infected tumour cells releases α virions. Virions are only produced during lysis and lose infectivity at a rate ω, leading to the dierential equations for I(t) and V (t) d dt
Clearance of proliferating cells leads to exponential loss as the cleared cells no longer divide nor return to quiescence. This is accounted for by updating equation (6) to include the loss of mitotic cells due to immune and viral mediated death, giving
Finally, the link between the oncolytic virus and the immune system is cytokine production, modelled by C prod (U (t)). Both lysis of infected cells and immune killing are immunogenic, leading to an increase in immune signalling. Therefore, we link virus and immune mediated cell death by the cytokine production rate C prod (U (t)), given by
We note that C prod (U (t)) C * prod > 0 for nonnegative cell populations; the homeostatic cytokine production rate is eectively the minimal cytokine production rate. Combining the dierential equations for each population with the PDF K(t) gives the complete model in equation (1).
Model analysis
The mathematical model in equation (1) represents cell populations which are non-negative quantities. Consequently, we begin our analysis by showing that solutions of equation (1) evolving from non-negative initial data remain non-negative. Lemma 3.1. Assume that the parameters in equation (1) are strictly positive and that the initial conditions are componentwise non-negative. Moreover, assume that G 1 (s) = φ G (s) 0 for s ∈ (−∞, 0]. Then solutions of the initial value problem corresponding to equation (1) are non-negative for all time t 0.
Proof. By the assumption on the initial conditions, C prod (U (0)) C * prod > 0, so d dt
We now investigate the populations Q(t) and G 1 (t).
, then Q(t) eventually becomes positive for some t > 0. Therefore, we only need to consider the case where Q(0) > 0 and φ(s) 0 for s ∈ (−∞, 0]. Now, let t g ∈ [0, ε C ] be the rst time that G 1 (t g ) = 0. Then A R (t) dened by equation (12) satises
Then
Thus G 1 (t) is strictly increasing at t g . If t g = 0, then G 1 (t) > 0 immediately. Conversely, if t g > 0, then G 1 (t) must be nonincreasing at t g . This contradicts equation (14), so no such t g > 0 can exist and
If V (0) = I(0) = 0, then the I(t), V (t) populations remain identically zero for all time. Therefore, we consider V (0) + I(0) > 0 and we have three cases:
Case I If V (0) = 0 then I(0) > 0 and it is simple to calculate that d dt
If Q(0) = 0 and φ(s) = 0 almost everywhere in (−∞, 0], the tumour free case, then Q(t), G 1 (t) and I(t) remain identically zero for all time t > 0 and V (t) decays exponentially to 0. Thus, as above, we need only consider Q(0) > 0 and G 1 (t) > 0 in (0, ε C ]. Now, I(0) = 0 so V (0) > 0 and for all t ∈ (0, ε C ], if I(t) = 0 then d dt
and I(t) > 0 for all t ∈ (0, ε C ], otherwise a contradiction ensues.
Case III Thus, it only remains to consider the case where V (t) and I(t) are both strictly positive immediately and remain positive in some neighbourhood of t = 0. While I(t) and V (t) are non-negative, we compute d dt
Then, each component is positive at t = ε C and the above argument extends from [0, ε C ] to [0, ∞).
3.1
Linearisation of the distributed DDE
The system (1) has the cancer free equilibrium (CFE), U * = (0, 0, 0, 0, C * , P * ). Although it is often convenient to regard a trajectory U (t) of the system (1) as a parameterised curve with with U (t) ∈ C(R, R 6 ), it is important to realise that the DDE system (1) denes an innite dimensional dynamical system. The innite-dimensional phase space is
where | · | is the 1 norm in R 6 , and µ is a probability measure whose Radon-Nikodym derivative with respect to the Lebesgue measure is K(t). When K(t) is Riemann integrable (such as in the case of the Gamma distribution that we will consider in Section 4) this implies that
This space satises the axioms given by Hale and Verduyn Lunel [1993] ; Hino et al. [1991] , so there exists a unique solution to the corresponding initial value problem.
To investigate the long term behaviour of the model, we linearise the system around the CFE in L 1 (µ).
In a similar procedure to Câmara De Souza et al. [2018] , we rst linearise the function A R (t), given in equation (12) around the CFE. Using the Taylor expansions of η(U (x)) and ψ G (U (x)), with η(U * ) = 0, we approximate the inner integral
The full expansion of e I is
Importantly, e I is multiplied by G 1 (t − σ) in A R (t) and any non-constant terms of U (t) in the expansion of e I are consequently nonlinear. So we obtain
We translate the CFE of equation (1) to zero by settingC(t) = C(t) − C * andP (t) = P (t) − P * with C * and P * given by equation (9). Then, noting that η(U * ) = 0 and using (15), the N (t) terms in the I(t) and V (t) equations are also nonlinear. Equation (1) 
We follow Smith [2011] to complete the linearisation. We dene X(t) := U (t) − U * and use X τ to denote the linear delayed terms via
By making the ansatz X(t) = Ce λt , we see that X τ (t) satises
where L[K](λ) is the Laplace transform of K(σ) dened by (5). Dropping the nonlinear terms in equation (16) and setting
we obtain the linearised innite dimensional DDE d dt
where
Hence equation (17) becomes
From equation (18), the characteristic equation is
Using the block nature of the linearisation matrix gives
Here ρ(λ) is the determinant of the lower triangular block and has strictly negative real roots. The explicit roots of ρ(λ) imply that the stability of the CFE is determined by the roots of p(λ).
To study the persistence of small tumours, we characterise the stability of the disease free steady state. Typically, for DDEs, this involves solving a transcendental equation with innitely many roots. To simplify the following analysis, we rst show that the rightmost root of the characteristic equation is real. This result is unsurprising, as a complex rightmost eigenvalue would give rise to spiralling solutions around the CFE, which would become negative, contradicting Lemma 3.1.
Lemma 3.2. For strictly positive parameters, the rightmost root of q(λ) is real.
Proof. First, we note from (5) that the Laplace transform of a non-negative function f , is a decreasing function of λ. Similarly,
is decreasing for real λ where it converges. Therefore, as a function of a real variable, p(λ) is continuous and p(λ) is strictly decreasing for λ > max[−(a 1 + d 1 + k p P * ), −(a 2 + d 2 + k p P * )] := −Θ.
Moreover,
so there is exactly one real root λ * of p(λ) that satises λ * > −Θ.
Since ρ(λ) has strictly negative real roots, any complex roots, ν = ν r + iν i with ν r ∈ (−Θ, ∞) and ν i = 0, of the characteristic equation q(λ) must solve p(ν) = 0, which we may rewrite as
Taking the magnitude of the equality (20) gives
However,
where the last equality comes from the nonegativity of the integrand. Substituting these bounds into equation (21) gives
from which we obtain 0 = p(ν r + iν i ) < p(ν r ).
Since p(λ) is strictly decreasing for λ > −Θ, we must have ν r < λ * . Then, the rightmost root of q(λ) is either λ * or a root of ρ(λ) and is real.
The preceding result simplies the analysis of the transcendental characteristic equation by ensuring that the critical characteristic root is real. Therefore, the stability of the CFE, and consequently, the persistence of small tumours, can be characterised using the intermediate value theorem.
Theorem 3.3. The cancer free equilibrium U * of equation (1) is locally stable if
and unstable if
Proof. The condition for stability is equivalent to p(0) < 0. In this case, since p(λ) is strictly decreasing for λ > max[−(a 1 + d 1 + k p P * ), −(a 2 + d 2 + k p P * )], there can be no real root of the characteristic equation with non-negative real part. Since the rightmost root must be real, all roots of the characteristic equation must have negative real part and the CFE is stable.
The condition for instability is equivalent to p(0) > 0. Since Using (5) we can rewrite the stability condition (22) as
This can be rearranged as a basic reproduction number type condition
Hence, the CFE is locally attracting if the product of the ratios of expected transit rates into and out of the quiescent and G 1 phases is less than one. Biologically, this corresponds to each cell that transits out of either the quiescence or G 1 phase not replacing itself through mitosis. Finally, we can characterise the importance of heterogeneity in cell cycle duration as a determining factor of disease progression. Let P be the parameter space of the distributed DDE (1). Following Campbell and Jessop [2009] , for each PDF K(t), we dene the stability region as Ω K = {p ∈ P | The CFE of (1) is locally asymptotically stable} .
Then, we are able to characterise the stability regions for certain PDFs with respect to the discrete DDE. For these PDFs, the tumour heterogeneity in cell cycle duration acts to destabilise the CFE and leads to more a robust tumour. We formalise this relationship in the following corollary.
Corollary 3.4. For any PDF K(t) which satises (3) andd K d 3 we have the inclusion Ω K ⊆ Ω δ .
Proof. Take p ∈ Ω K so that equation (23) is satised and the CFE is locally stable. Now, we dene
It is simple to see that h K (x) is convex. Jensen's inequality gives
It follows that
so the CFE is stable in the discrete DDE case and p ∈ Ω δ .
which can be viewed as a measure of the skewness of the PDF K(t). Using equation (3), this condition is satised if
It is important to note that the linearisation only determines local stability. So, while small tumours may not grow, large tumours do not necessarily disappear. In fact, for a given level of immune recognition of tumour cells, k p , there is a critical tumour size above which the tumour grows unboundedly. The critical tumour size acts as a separatrix between tumour extinction and growth and takes the form of a nonzero equilibrium point where tumour growth and immune surveillance are balanced. In Theorem 3.5, we show that such an equilibrium must exist. Transition across this equilibrium has been hypothesised to occur as part of the cancer immunoediting process that allows tumours to grow and corresponds to a transient decrease of k p [Bhatia and Kumar, 2011; Mittal et al., 2014; Swann and Smyth, 2007] .
To emphasise the biological interpretation of Theorem 3.5, we use the stability condition as written in equation (23) to characterise the existence of the non-zero equilibrium.
Theorem 3.5. Assume that the parameters in equation (1) 
Then, for k p > k crit p , there exists a strictly positive untreated equilibrium solutionȲ * 1 = (Q,Ḡ 1 , 0, 0,C,P ) of equation (1) with Q 1 and G 1 strictly positive.
Proof. First, in the absence of viral treatment, V (0) = 0 and I(0) = 0, so (V * , I * ) = (0, 0). To simplify notation in the proof, we set ξ i = a i + d i + k p P * for i = 1, 2. We consider the dierential equation for G 1 (t) at equilibrium, so d dt G 1 (t) = 0 and
This can be rearranged as a quadratic equation in
whose positive root is a function of Q * dened by
Now, inserting G * 1 (Q * ) into d dt Q(t) = 0 gives
Using (4) gives
The equilibrium concentration Q 1 must therefore solve f (Q 1 ) = 0. A simple calculation shows that f (0) = 0, so we search for Q 1 positive. Now, as Q * → ∞,
This is equivalent to
determines the sign of f (Q * ) as Q * grows innitely large. Now,
so f (Q * ) grows innitely large with Q * and must be positive for large values of Q * . Next, as Q * → 0,
Taylor expanding the square root about the point Q * = 0 gives
Thus, the sign of f (0) is determined by the sign of
The function g(k p ) is strictly decreasing with g(k crit p ) = 0, therefore, f (0) < 0 for k p > k crit p .
Consequently, f (Q * ) is negative for Q * small and positive, and positive for large Q * , so there must be a positive rootQ with f (Q) = 0. This root denes a solutionḠ 1 = G * 1 (Q 1 ) of equation (24). Finally, we can write an equilibrium solution of d dt P (t) = 0 as a function of C(t) viā
Given the upper bound ofP and the pair (Q,Ḡ 1 ), the function Ψ(U (t)) is bounded. Therefore, there must exist a solutionC > 0 to
Finally, using the value ofC, we can calculate the corresponding equilibriumP .
The Gamma Distribution and Equivalent ODE System
To translate our results for a generic distribution into predictions of tumour growth, we must specify a distribution of cell cycle durations, corresponding PDF K(t), and death rated K . We assume that cell cycle durations follow a gamma distribution, so K(t) = g j a (t). The function g j a (t) is the PDF of the gamma distribution with
The real positive parameters a and j in equation (25) dene the shape of the gamma distribution. The expected cell cycle duration is τ = j/a. For given τ we take j to be a strictly positive integer and determine a by a = j/τ . The standard deviation, s 2 , of the gamma distribution is given by s 2 = τ 2 /j. For xed τ , larger values of j result in a more concentrated distribution about τ . In Appendix A we demonstrate that in the limit as j → ∞ (with xed τ ) the gamma distributed model converges in distribution to a delta distributed model with discrete delay τ .
To calculated g , we note that the expected cellular output of the cell cycle is
Imposing the equality (7) and τ = j/a gives
Therefore,d g is given byd
Equivalent ODE Formulation
The link between gamma distributed DDEs and transit chain ODEs has been known since at least the 1960s [Vogel, 1961] . The equivalence between innite dimensional DDEs and ODEs is typically established through the linear chain technique. Among many other areas, the linear chain technique has recently been used in the pharmaceutical sciences [Câmara De Souza et al., 2018; Hu et al., 2018] . More generally, the equivalence between distributed DDEs and ODEs was studied by Diekmann et al. [2017] .
Typical applications of the linear chain technique involve a transit chain type ODE without growth or loss throughout the chain. In the example of cellular growth represented by a transit chain model, the number of cells is conserved throughout the delayed process. Here, we derive a variant of the linear chain technique that accounts for the exponential decay of the mitotic cell population due to apoptosis, immune pressure and lysis as modelled in equation (1). The resulting ODE system is a compartment model with linear clearance throughout the transit chain. By taking K(t) = g j a (t) with j ∈ N and a = k tr = j/τ and setting
we can reduce the distributed DDE model to a system of ODEs. We show in Theorem 4.2 that equation (1) is equivalent to the system of ODEs
with identical initial conditions to the distributed DDE for Q(0), V (0), I(0), P (0), C(0) and
where φ(s) is the history function of equation (1).
Lemma 4.1. For an integrable function G 1 (t) and j ∈ N with a = k tr = j/τ , the vector with i-th component given by
is the solution of the system of dierential equations given by
Proof. Using the Lebniz and product rules, we dierentiate A 1 (t) to obtain d dt
Computing the derivative of the exponential then gives d dt
Similarly for general i, dierentiating the expression for A i (t) from (28) gives
Thus, the vector A(t) = [A 1 (t), A 2 (t), ..., A j (t)] satises equation (29).
Comparing equations (30) and (31) shows that the exponential loss of cells during the cell cycle in equation (1) corresponds to linear clearance in the equivalent transit compartment system of ODEs. We now show the equivalence of the ODE and DDE models by using Lemma 4.1 to replace the integral terms in equation (1).
Theorem 4.2. The system of distributed DDEs (1) with K(σ) = g j a (σ),d g as given in (26) and initial conditions Q(0) = Q 0 , I(0) = I 0 , C(0) = C 0 and history functions V (s) = φ V (s), P (s) = φ P (s) and G 1 (s) = φ G (s) for s ∈ (−∞, 0] is equivalent to the system of ODEs (27) with initial conditions Q(0) = Q 0 ,
Proof. Using Lemma 4.1, we see that
Thus, the dierential equations for Q(t) in (1) and (27) are equivalent. The remaining terms in equation (27) are exactly those in equation (1). To nish the conversion from the DDE (1) to the ODE (27), we must specify the initial conditions. Given the history functions [φ G (s), φ V (s), φ P (s)] from the DDE model, we chose the initial conditions A i (0) of equation (27) according to equation (32). This ensures that the solution of equation (27) is equivalent to the solution of equation (1) [Smith, 2011] .
To convert from the ODE (27) to the DDE (1), we must take care with the construction of the history
The ODE is equipped with initial conditions V (0) and P (0). For simplicity, we set φ V (s) = V (0) and φ P (s) = P (0). The j initial conditions for each A i (0) dene j constraints on φ G (s). There are many history function that satisfy these constraints and the ODE reduction of the DDE denes the same solution for each such history function. We show how to construct one such history function φ G ∈ L 1 ((−∞, 0], R, µ). Let the ODE system have initial conditions α i = A i (0) for i = 1, 2, ..., j and α i ∈ R, and chose a sequence of points
Now, we make the following ansatz for φ G (s)
where δ(x) is the Dirac function. We will show that is possible to chose the {b n } j n=1 such that
However, the histories φ V (s), φ P (s) and φ G (s) appear in the integral term
so some care is needed. We have already set φ V (s) = V (0) so η(U (s) is dened on (−∞, 0], so we need only consider
Since ψ G only appears in a Lebesgue integral and diers from k p P (0) on a set of measure 0, the following holds Therefore, nding {b n } j n=1 such that equation (34) holds is equivalent to nding {b n } j n=1 such that
Using the ansatz for φ G in equation (35) gives the following system of equations for i = 1, 2, ..., j
To simplify notation, set µ n = 0 −xnd g + η(U (s)) + k p P (0)ds and note µ n is independent of the unknowns {b n } j n=1 . Equation (36) denes a linear system of equations for the unknowns {b n } j n=1 . Consequently, there exists a unique solution to (36) if the matrix
is invertible. To show this matrix is invertible, we will show that det(A) = 0. Using the denition of g j ktr (x i ), the m-th column has a common factor of a 2 k tr e −ktrxm exp [−µ m ] > 0 while, the n-th row has a common factor of k n tr /(n − 1)! > 0 for n, m = 1, 2, .., j. Thus
Consequently, det(A) = 0 so A is invertible and we can uniquely determine the {b n } j n=1 .
The equivalence between ODEs and gamma distributed DDEs has been used extensively since Vogel [1961] . Some authors have shown how to convert ODE transit compartment models to distributed DDE for specic initial conditions [Câmara De Souza et al., 2018; Cooke and Grossman, 1982] . However, to the author's knowledge this is the rst proof of direct equivalence between an ODE and a distributed DDE for arbitrary ODE initial conditions established by explicitly constructing a suitable history function.
Numerical Results
For the purpose of numerical simulation, the system of nite dimensional ODEs derived in Section 4.1 is much more tractable than the distributed DDE. Numerically solving the distributed DDE requires the development and implementation of a numerical dierential equation solver capable of accurately computing the semi-innite convolution integral, while there are numerous existing methods for solving systems of ODEs. To solve the DDE given in equation (1), we simulate the equivalent ODE in equation (27) and calculate N (t) as shown in Appendix B to illustrate the analytical results of Section 3. For simplicity, we only present the dynamics of Q(t), as these dynamics are representative of the full model's behaviour. The parameters used in these simulations are given in Table 1 . The smallest detectable tumour size has been estimated to be roughly 2 30 ≈ 1 × 10 9 cells [Carlson, 2003; Schwartz, 1961] . As viral oncology has only been approved for advanced melanoma, we consider tumours with approximately 10 10 cells. (This corresponds to viral treatment starting 4 tumour doublings after diagnosis.) To ensure that our numerical computations involve numbers of similar magnitude, we measure the number of tumour cells in units of 10 10 cells. Given the homeostatic approximation of leukocytes (≈ 6 × 10 9 cells/L) and roughly 7 litres of blood, we measure the phagocyte concentration in identical units, namely 10 10 cells.
To illustrate the dierence between distributed and discrete delays in the cell cycle duration, we simulate equation (27) without viral therapy for j = 6 and the discrete delay case in Figure 2 a) . In Figure 2 b) , we show the discrete case and the gamma distributed case when j = 50. These simulations show that the discrete delay case has a larger basin of attraction than the distributed delay case. This is unsurprising, since for both j = 6 and j = 50, the result of Corollary 3.4 holds, so all parameter regimes leading to stability of the CFE for the gamma distributed DDE also lead to stability of the CFE in the discrete delay (27) in Figure 3 . C 1/2 was calculated from the homeostatic phagocyte production rate and k p was calculated from the mass-action tumour-immune interaction from Liu et al. [2007] . C max prod was calculated from G-CSF response to infection [Pauksen et al., 1994] . η 1/2 was chosen to ensure a high initial infectivity of viral therapy while k q,s and Ψ 1/2 were selected to give physiologically realistic simulations.
case. Biologically, this corresponds to increased cell cycle duration heterogeneity leading to more robust tumours. In Figure 2 , we also show the impact of including tumour-immune interaction by comparing our model with that of Crivelli et al. [2012] . We compare the results of our simulation with tumour-immune interaction (k p = 0.065) with the Crivelli model (k p = 0) as written in Appendix A. This simulation underlies the importance of tumour-immune interaction in determining disease progression. In Appendix A, we show that the gamma distribution converges to the degenerate distribution as j grows innitely large, with τ > 0 held constant. The case j = 1 corresponds to an exponential distribution of cell cycle durations. In what follows, we assume that the distribution of cell cycle durations is neither exponential nor degenerate, so 1 < j < ∞. In the numerical simulations that follow, we illustrate a representative case of our results with j = 6. In Figure 3 , we simulate the nite dimensional representation of the distributed DDE (1) for dierent levels of immune recruitment, k cp , during viral therapy. Figure 3 shows that changing k cp changes the long-term success or failure of viral treatment. Suciently large values of k cp induce long-lasting remission while smaller values of k cp lead to eventual tumour progression after oncolytic virus treatment. Figure 4 shows the impact of parameter variability on stability of the CFE. Figure 4 (a) shows that increased immune interaction (k p ) can counteract fast transit between quiescence and mitosis (a 1 and a 2 respectively) to ensure stability of the CFE. Moreover, suciently slow entrance into the active phase of the cell cycle (small a 2 ) also stabilises the CFE. Figure 4 Figure (a) shows the simulation of equation (1) with a gamma distribution for j = 6 in blue, a discrete delay in red and the Crivelli model (equation (37)) in black. Figure (b) shows the simulation of equation (1) with a gamma distribution for j = 50 in blue, a discrete delay in red and the Crivelli model (equation (37)) in black. Figure 3 : Simulated viral therapy with limited and sucient immune recruitment. The parameters used in sucient immune recruitment are given in Table 1 . Limited immune recruitment occurs with k cp = 1.63 and other parameters as given in Table 1. large to account for less ecient immune-tumour interaction (k p ), while a large death rate during the cell cycle (d g ) can ensure stability of the CFE regardless of immune involvement. These investigations conrm the impact of immune recruitment and clearance of tumour cells. This result indicates that increasing immune involvement is important in developing therapeutic strategies. Finally, Figure 5 shows the relationship between the nonzero equilibrium found in Theorem 3.5 and the parameter k p . The diagram indicates that the CFE gains stability through a transcritical bifurcation as k p Figure (a) shows the relationship between the stability of the CFE and the parameters k p , a 1 and a 2 . Figure (b) shows the relationship between stability of the CFE and the parameters k cp , k p andd g . increases. For k p > k crit p and initial conditions straddling the unstable equilibirum, we see the dependence of asymptotic behaviour on initial conditions. A similar relationship exists between the stability of the CFE and k cp . Biologically, Figure 5 (b) shows that the same immune system can control small tumours while large established tumours grow unboundedly.
Discussion
Malignant tumours are comprised of an extremely heterogeneous population of malignant cells. Oncolytic viruses combat this heterogeneity by exploiting two common characteristics of malignant cells: weakened antiviral immunity and explosive growth rates. Once an oncolytic virus has inltrated a tumour, lysis of infected cells and immune recruitment combine to eliminate the tumour. Past models of tumour growth and viral oncology have used discrete DDEs to model the cell cycle duration and infection of susceptible cells. However, discrete DDEs enforce a uniform and constant tumour cell cycle time and do not incorporate any aspect of the inherent heterogeneity of malignant cells inside the tumour microenvironment. In this work, we produced a mathematical model of tumour cell growth that incorporates the heterogeneity of tumour reproduction speed by modelling cell cycle duration as a random variable following a PDF K(t). This framework is a novel representation of tumour growth and is more physiologically realistic than the discrete delay case. Specically, variation in tumour cell cycle duration can be seen as a measure of tumour cell heterogeneity. Using linear stability analysis, we established the relationship between the expected number of cells surviving the cell cycle and tumour remission. As we assumed a constant death rate throughout the cell cycle, the expected number of cells surviving the cell cycle is directly related to the distribution of cell cycle durations. The distribution of cell cycle durations and disease progression are explicitly linked in our stability threshold. The stability threshold determines the minimal anti-tumour immune response that ensures that nascent tumours do not persist. This result shows that increasing immune involvement can stabilise the tumour free state regardless of the cancer growth rate.
Our results indicate that lysis of infected cells and increased immune recruitment act synergistically to eliminate tumour cells during viral therapy. Our simulations show that the combination of viral therapy and the resulting immune recruitment function by driving solutions across a separatrix into the basin of attraction of the tumour free equilibrium. If immune recruitment is insucient to control tumour growth, we predict that viral therapy will drive initial tumour remission that is followed by disease recurrence. Moreover, our results show that viral therapy can act as the external force required to shrink tumours to a size manageable by the immune system, leading to long-term remission. These observations are consistent with clinical results and suggest that oncolytic viruses designed to maximise immune response may have clinical benets. Finally, our modelling techniques develop a novel mathematical treatment of tumour cell growth by using a distributed DDE. The distributed DDE considered in this work incorporates the discrete delay case studied by Crivelli et al. [2012] and others for a suitable choice of K(t) and k p . In the specic case of a gamma distribution, we derive a novel linear chain technique that incorporates cellular loss throughout the cell cycle. Using this technique, we reduce the innite dimensional distributed DDE to an equivalent nite dimensional ODE. Our derivation of the equivalent ODE formulation is easily generalisable to physiological processes with exponential growth or decay. The reduction of the distributed DDE to an ODE oers a method whereby models using discrete DDEs can include more physiologically realistic distributed delays without losing the ability to easily simulate the model. Our modelling framework has certain limitations. The mathematical model greatly simplies immune recruitment and tumour-immune interactions in favour of an analytically tractable model. The interactions between the legion of cytokines and immune cell types in the tumour micro-environment are not considered in this work, nor have we studied the eect of immune system selection of cancer cells. This modelling work raises the interesting question of which distribution best models tumour cell cycle durations. Most existing models either use the discrete or gamma distribution to exploit the existing numerical methods to simulate these models. Without data, it is dicult to determine which distribution most accurately models tumour cell cycle durations. Nevertheless, our analytic results are valid for any distribution describing tumour cell cycle durations. In summary, our model incorporates an aspect of tumour cell heterogeneity, makes predictions that are consistent with clinical observations and indicates future avenues of oncolytic virus development.
We show that the Crivelli model [Crivelli et al., 2012 ] is a special case of the general distributed DDE model (1) developed in Section 2 without immune recruitment. We do this two ways, rst by showing that the discrete DDE model corresponds to the distributed DDE model with a degenerate distribution. Then alternatively by showing that the discrete DDE model can be recovered from the distributed DDE model in a suitable limit when K(t) is taken to be a Gamma distribution. Crivelli et al. [2012] do not consider tumour-immune involvement, so we take kp = 0 in (1). Then, the immune recruitment has no impact on the tumour model, so we drop the dierential equations for P (t) and C(t). Crivelli et al. [2012] use a discrete DDE to model the cell cycle duration. The simplest way to recover a discrete DDE from a distributed DDE is to let K(t) = δ(t − τ ). Then, equation (7) gives d δ = d3. Thus the model (1) and taking η(U (t)) to be the non-dierentiable contact rate η(U (t)) = κ V (t) V (t) + I(t) + G1(t) + N (t) + Q(t) , returns the mathematical model in Crivelli et al. [2012] . To illustrate that their results are a special case of ours, we use Theorem 3.3 to determine the stability of the CFE for the Crivelli model. With kp = 0 and K(t) = δ(t − τ ), it is simple to calculate that ΨG 1 = 0 and L[δ(t − τ )](d3) = e −d 3 τ .
Then the stability condition (22) becomes
which is exactly the same as found by Crivelli et al. [2012] .
We have shown that discrete DDEs can be modelled as degenerate distributed DDEs. Next, we show a distinct method of reducing the general distributed DDE to a discrete DDE by considering a gamma distributed DDE, i.e. K(t) = g j k tr (t), in the limit as j → ∞. We parameterise the gamma distribution by choosing j ∈ N and setting aj = τ /j. Then, for each integer j, the expected duration of the cell cycle is τ . Moreover, the standard deviation is given by s 2 j = τ 2 /j with lim j→∞ s 2 j = 0.
Heuristically, as j increases, g j a (t) becomes increasingly concentrated about the expected value, τ . Formally, the characteristic function of the gamma distribution converges in distribution to the characteristic function of the δ(t − τ ) distribution with ∞ 0 y(t − σ)g j j/τ (σ)dσ → y(t − τ ) as j → ∞ for any test function y(t). From equation (26),dg is dependent on the parameter j viâ d j g = j τ (e d 3 τ ) 1/j+1 − 1 .
To compute the limit ofd j g as j → ∞, we rst note that lim n→∞ n(a 1/n − 1) = lim n→∞ a 1/n − 1 1/n = d dt a t t=0 = ln(a).
Therefore, lim j→∞d j g = lim j→∞ j τ (e d 3 τ ) 1/j+1 − 1 = 1 τ ln(e d 3 τ ) = d3, sod j g converges to the death rate of the discrete DDE as j → ∞. Finally, we compute the linearisation matrix for the linearised DDE (17) with K(t) = g j a (t):
and the corresponding characteristic function, once again using equation (19), q(λ) = ρ(λ) 2a1a2 a j (a + λ +dg + kpP * ) j − (a1 + d1 + kpP * + λ)(a2 + d2 + kpP * + λ) .
Using Theorem 3.3, the condition for stability of the CFE is 2a1a2 a j (a +dg + kpP * ) j − (a1 + d1 + kpP * )(a2 + d2 + kpP * ) < 0.
Using a = j/τ , we rearrange this condition to nd a cell cycle duration, τj, that ensures local stability of the CFE τj > ĵ d j g + kpP * 2a1a2 (a1 + d1 + kpP * )(a2 + d2 + kpP * )
Then, the minimal cell cycle duration for stability, τ * j , is given by τ * j = ĵ d j g + kpP * 2a1a2 (a1 + d1 + kpP * )(a2 + d2 + kpP * ) 1/j − 1 and is dependent on the parameter j. Once again, using equation (39), we see that lim j→∞ τ * j = lim j→∞ ĵ d j g + kpP * 2a1a2 (a1 + d1 + kpP * )(a2 + d2 + kpP * ) 1/j − 1 = 1 d3 + kpP * ln 2a1a2 (a1 + d1 + kpP * )(a2 + d2 + kpP * ) .
Thus the critical cell cycle duration when K(t) = g j a (t) converges to the critical cell cycle duration time in discrete delay case case. Moreover, when kp = 0, τ * j converges to the critical delay time found by Crivelli et al. [2012] . Consequently, the discrete DDE model considered by Crivelli et al. [2012] can be considered a degenerate case of the distributed DDE or as a limit of a gamma type distributions.
